| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Elderly, Adult |
| State: | Powder |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product name | Meloxicam |
| Cas number | 71125-38-7 |
| Density | 1.613 |
| MF | C14H13N3O4S2 |
| Melting point | 255°C |
Meloxicam is a non-steroid antipyretic, analgesic and anti-inflammatory drug. It is not a hormone drug and has strong anti-inflammatory, analgesic and antipyretic effects. It can selectively inhibit the activity of cyclocxygenase-2 (COX-2), thereby blocking the synthesis of prostaglandins. The inhibition of prochemicalbook adenosin biosynthesis in inflammatory sites was stronger than that of prostaglandin biosynthesis in gastric mucosa or kidney, and was safer than other NSAIDs. It is mainly used to relieve the symptoms of osteoarthritis, painful osteoarthritis, rheumatoid arthritis and severe spondylitis of the joints.
Older patients and patients with an increased risk of adverse reactions;
In elderly patients, patients with rheumatoid arthritis and ankylosing spondylitis treatment recommended dose for 7.5mg/days. Starting dose in patients with increased risk of adverse reactions to 7.5mg/days.
Patients with renal insufficiency:
Patients with severe renal failure and need dialysis, the dose should not exceed 7.5mg/days.
Patients with mild to moderate renal insufficiency do not need to adjust the dosage (such as patients with creatinine clearance greater than 25ml/minutes).
Patients with severe renal failure without dialysis.
Patients with hepatic insufficiency: In patients with mild and moderate hepatic insufficiency no need to adjust the dose.
In patients with severe hepatic insufficiency.
Children: This product is not for use in children under 15 years of age. Meloxicam has other forms, may apply.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}